Financial Survey: Centogene (NASDAQ:CNTG) versus InVitae (NASDAQ:NVTA)
Centogene (NASDAQ:CNTG) and InVitae (NYSE:NVTA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.
Earnings and Valuation
This table compares Centogene and InVitae’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Centogene||$54.64 million||3.88||-$23.36 million||($1.46)||-7.31|
|InVitae||$216.82 million||23.71||-$241.96 million||($2.28)||-17.11|
Institutional & Insider Ownership
6.8% of Centogene shares are owned by institutional investors. Comparatively, 98.6% of InVitae shares are owned by institutional investors. 2.9% of InVitae shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Centogene and InVitae’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations and price targets for Centogene and InVitae, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Centogene currently has a consensus target price of $21.50, indicating a potential upside of 101.50%. InVitae has a consensus target price of $33.54, indicating a potential downside of 14.02%. Given Centogene’s stronger consensus rating and higher probable upside, research analysts clearly believe Centogene is more favorable than InVitae.
Centogene beats InVitae on 7 of the 11 factors compared between the two stocks.
Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene B.V. was founded in 2006 and is headquartered in Rostock, Germany.
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company also operates AltaVoice, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.